// App-Quantinova.ai

: B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

Researchers

Presenter

  • Margaret Ragni

Principal Investigators

  • Roshni Kulkarni

  • K. John Pasi

  • Kathelijn Fischer

  • Johnny Mahlangu

  • Amy Shapiro

  • Beatrice Nolan

  • Johannes Oldenburg

  • Tadashi Matsushita

  • Annemieke Willemze

  • Huixing Yuan

  • Dan Rudin

Medical Centers

  • University of Pittsburgh, Pittsburgh, PA

  • Michigan State University, Lansing, MI

  • Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry, London, United Kingdom

  • Hematology and Van Creveld Cinic, University Medical Center Utrecht, Utrecht, Netherlands

  • Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa

  • Indiana Hemophilia & Thrombosis Center, Indianapolis, IN

  • Our Lady's Children's Hospital, Dublin, Ireland

  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

  • Nagoya University Hospital, Nagoya, JPN

  • Sobi, Stockholm, Sweden

  • Bioverativ, a Sanofi Company, Waltham, MA, United States

  • Bioverativ, a Sanofi Company, Waltham, MA, United States

Locations

  • United States

  • United Kingdom

  • Netherlands

  • South Africa

  • Ireland

  • Germany

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Infectious Diseases (ID)

Disease

  • Hemophilia

  • Tuberculosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01027364

  • NCT01440946

  • NCT01425723

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved